clinical trial · NCT06792825
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
Masonic Cancer Center, University of Minnesota·phase2·recruiting·n = 65
Follicular LymphomaMarginal Zone LymphomaTafasitamabRituximabLenalidomide
brief summary
The study follows a Simon's two-stage phase II trial design to evaluate the safety and efficacy of tafasitamab added to rituximab and lenalidomide for two treatment-naïve, parallel, independent cohorts: follicular lymphoma (FL) and marginal zone lymphoma (MZ). Each cohort, FL and MZ, will be evaluated separately. This study is presented to the patient and consent is signed prior to the initiation of treatment for their primary malignancy.
started
Aug 7, 2025
primary completion
Jul 8, 2029
completion
Jul 8, 2031
last updated
Aug 12, 2025
official title
HM2023-43: A Phase 2 Trial of Tafasitamab in Combination With Lenalidomide+Rituximab in Treatment-naive Follicular Lymphoma and Marginal Zone Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol